Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

756
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
756
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin-Tazobactam in Obese Patients.

European journal of drug metabolism and pharmacokinetics·2021
Same author

Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.

Infection·2020
Same author

Use of Individual Pharmacokinetics to Improve Time to Therapeutic Vancomycin Trough in Pediatric Oncology Patients.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2018
Same author

A simple and rapid RP-HPLC method for the simultaneous determination of piperacillin and tazobactam in human plasma.

Journal of pharmaceutical and biomedical analysis·2016
Same journal

Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa: A Multicenter Retrospective Cohort Study.

Hospital pharmacy·2026
Same journal

Stability of Diluted Intravenous Metronidazole in 0.9% Sodium Chloride.

Hospital pharmacy·2026
Same journal

Response to Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Significant Published Articles in 2025 for Pharmacy Nutrition Support Practice.

Hospital pharmacy·2026
Same journal

Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Comparison of Cystatin C-Based and Serum Creatinine-Based Renal Function Estimates Against Timed Urine Collection in Critically Ill Patients.

Hospital pharmacy·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Case report: dabigatran-associated gynecologic bleeding.

S Alexander Winans1, Adetola Ademolu2

  • 1PGY1 Pharmacy Resident, Harris County Hospital District, Houston, Texas.

Hospital Pharmacy
|January 15, 2014
PubMed
Summary
This summary is machine-generated.

Dabigatran, a medication for atrial fibrillation, was linked to a case of major gynecological bleeding in a patient. The bleeding resolved after discontinuing dabigatran, highlighting a potential adverse effect.

Keywords:
dabigatrangynecologic bleedmajor hemorrhage

Related Experiment Videos

Last Updated: May 4, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Gynecology

Background:

  • Atrial fibrillation (AF) necessitates anticoagulation therapy.
  • Dabigatran is a direct thrombin inhibitor used for AF treatment.
  • Anticoagulants carry a risk of bleeding complications.

Purpose of the Study:

  • To report a case of major gynecological bleeding.
  • To investigate the potential association between dabigatran and gynecological hemorrhage.
  • To highlight a rare adverse effect of dabigatran therapy.

Main Methods:

  • Case report of a 33-year-old female patient.
  • Review of patient's medical history and medication.
  • Clinical observation of bleeding and response to drug discontinuation.

Main Results:

  • Patient experienced menorrhagia and significant blood loss (hemoglobin 7.1 g/dL) after starting dabigatran.
  • Gynecological bleeding ceased upon discontinuation of dabigatran.
  • Patient was transitioned to warfarin for AF management without further bleeding.

Conclusions:

  • Dabigatran therapy may be associated with major gynecological bleeding.
  • Discontinuation of dabigatran can effectively manage this adverse event.
  • Careful patient selection and monitoring are crucial for anticoagulation therapy.